4 unchanged sentences
Pursuant to this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of December 31, 2022, the end of the period covered by this report, our disclosure controls and procedures were effective.
−Removed: We have concluded that the consolidated financial statements in this Annual Report on Form 10-K fairly present, in all material respects, our financial position, results of operations and cash flows as of the dates, and for the periods, presented, in conformity with U.S.
+Added: We have concluded that the consolidated financial statements in this Annual Report on Form 10-K fairly present, in all material respects, our financial position, results of operations and cash flows as of the dates, and for the periods, presented, in conformity with GAAP.
(b) Management’s Annual Report on Internal Control Over Financial Reporting:
75 unchanged sentences
2015 Equity Incentive Plan (previously filed as Exhibit 10.1 to Registrant’s Current Report on Form 8-K, originally filed with the SEC on May 22, 2015, and incorporated herein by reference).
−Removed: 2018 Equity Incentive Plan (previously filed as Exhibit 10.1 to Registrant’s Current Report on Form 8-K originally filed with the SEC on June 1, 2018, and incorporated herein by reference)).
−Removed: Employment Agreement by and between Cyclacel Pharmaceuticals, Inc.
−Removed: and Spiro Rombotis, dated as of January 1, 2014 (previously filed as Exhibit 10.4 to the Registrant’s Annual Report on Form 10-K, originally filed with the SEC on March 24, 2014, and incorporated herein by reference).
−Removed: Employment Agreement by and between Cyclacel Pharmaceuticals, Inc.
−Removed: and Paul McBarron, dated as of January 1, 2014 (previously filed as Exhibit 10.5 to the Registrant’s Annual Report on Form 10-K, originally filed with the SEC on March 24, 2014, and incorporated herein by reference).
+Added: Amended and Restated 2018 Equity Incentive Plan (previously filed as Exhibit 10.1 to Registrant’s Current Report on Form 8-K originally filed with the SEC on June 16, 2022, and incorporated herein by reference.
Form of Change in Control Agreement by and between Cyclacel Pharmaceuticals, Inc.
4 unchanged sentences
4 to License Agreement between Daiichi Sankyo Company, Limited and Cyclacel Limited, dated July 11, 2011 (previously filed as Exhibit 10.2 to the Registrant’s Quarterly Report on Form 10-Q, for the quarterly period ended June 30, 2011, originally filed with the SEC on August 12, 2011, and incorporated herein by reference).
−Removed: Employment Extension Agreement, by and between Cyclacel Pharmaceuticals, Inc.
−Removed: and Spiro Rombotis, dated as of December 22, 2016 (previously filed as Exhibit 10.14 to the Registrant’s Annual Report on Form 10-K, originally filed with the SEC on March 1, 2017, and incorporated herein by reference).
−Removed: Employment Extension Agreement, by and between Cyclacel Pharmaceuticals, Inc.
−Removed: and Paul McBarron, dated as of December 22, 2016 (previously filed as Exhibit 10.15 to the Registrant’s Annual Report on Form 10-K, originally filed with the SEC on March 1, 2017, and incorporated herein by reference).
−Removed: Employment Extension Agreement, by and between Cyclacel Pharmaceuticals, Inc.
−Removed: and Spiro Rombotis, dated as of June 27, 2017 (previously filed as Exhibit 10.1 to the Registrant’s Current Report on Form 8-K, originally filed with the SEC on June 27, 2017, and incorporated herein by reference).
−Removed: Employment Extension Agreement, by and between Cyclacel Pharmaceuticals, Inc.
−Removed: and Paul McBarron, dated as of June 27, 2017 (previously filed as Exhibit 10.2 to the Registrant’s Current Report on Form 8-K, originally filed with the SEC on June 27, 2017, and incorporated herein by reference).
−Removed: Employment Agreement, by and between Cyclacel Pharmaceuticals, Inc.
−Removed: and Spiro Rombotis, dated as of December 6, 2017 (previously filed as Exhibit 10.1 to the Registrant’s Current Report on Form 8-K, originally filed with the SEC on December 12, 2017, and incorporated herein by reference).
−Removed: Employment Agreement, by and between Cyclacel Pharmaceuticals, Inc.
−Removed: and Paul McBarron, dated as of December 6, 2017 (previously filed as Exhibit 10.2 to the Registrant’s Current Report on Form 8-K, originally filed with the SEC on December 12, 2017, and incorporated herein by reference).
Clinical Collaboration Agreement by and between Cyclacel Pharmaceuticals, Inc.
1 unchanged sentence
Anderson Cancer Center dated as of August 21, 2018 (previously filed as Exhibit 10.1 to the Registrant’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2018 and incorporated herein by reference).
−Removed: Employment Agreement, by and between Cyclacel Pharmaceuticals, Inc.
−Removed: and Spiro Rombotis, dated as of January 1, 2019 (previously filed as Exhibit 10.1 to the Registrant’s Current Report on Form 8-K, originally filed with the SEC on January 7, 2019, and incorporated herein by reference).
−Removed: Employment Agreement, by and between Cyclacel Pharmaceuticals, Inc.
−Removed: and Paul McBarron, dated as of January 1, 2019 (previously filed as Exhibit 10.2 to the Registrant’s Current Report on Form 8-K, originally filed with the SEC on January 7, 2019, and incorporated herein by reference).
Cyclacel Pharmaceuticals, Inc.
3 unchanged sentences
Form of Securities Purchase Agreement (previously filed as Exhibit 10.1 to the Registrant’s Current Report on Form 8-K, originally filed with the SEC on December 22, 2020, and incorporated herein by reference).
−Removed: Employment Extension Agreement by and between Cyclacel Pharmaceuticals, Inc.
−Removed: and Spiro Rombotis, dated as of January 14, 2021 (previously filed as Exhibit 10.1 to the Registrant’s Current Report on Form 8-K, originally filed with the SEC on January 15, 2021 and incorporated herein by reference).
−Removed: Employment Extension Agreement by and between Cyclacel Pharmaceuticals, Inc.
−Removed: and Paul McBarron, dated as of January 14, 2021 (previously filed as Exhibit 10.2 to the Registrant’s Current Report on Form 8-K, originally filed with the SEC on January 15, 2021 and incorporated herein by reference).
Form of Retirement Agreement, by and between Cyclacel Pharmaceuticals, Inc.
4 unchanged sentences
and Paul McBarron (previously filed as Exhibit 10.2 to the Registrant’s Current Report on Form 8-K, originally filed with the SEC on June 17, 2021 and incorporated herein by reference).
+Added: Extension Agreement by and between Cyclacel Pharmaceuticals, Inc.
+Added: and Spiro Rombotis, effective as of January 1, 2023 (previously filed as Exhibit 10.1 to the Registrant’s Current Report on Form 8-K, originally filed with the SEC on December 30, 2022 and incorporated herein by reference).
+Added: Extension Agreement by and between Cyclacel Pharmaceuticals, Inc.
+Added: and Paul McBarron, effective as of January 1, 2023 (previously filed as Exhibit 10.2 to the Registrant’s Current Report on Form 8-K, originally filed with the SEC on December 30, 2022 and incorporated herein by reference).
+Added: Form of Indemnification Agreement for directors.
Subsidiaries of Cyclacel Pharmaceuticals, Inc.
39 unchanged sentences
March 8, 2023
−Removed: /s/ Gregory Hradsky
+Added: /s/ Kenneth Ferguson
March 8, 2023
−Removed: Gregory Hradsky
+Added: Kenneth Ferguson
Brian Schwartz
6 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.